Latest Articlesddd
Positive Results from Korsuva for Pruritis Cara Therapeutics Postive Results from Korsuva Trial On May 29, …
Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …
Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …
Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …
Vertex’s Good News Vertex and Kymera Therapeutics Collaboration Last week Vertex Pharmaceuticals (VRTX) and Kymera Therapeutics entered …
Great News for Array BioPharma Array BioPharma (ARRY) announced positive results from the interim analysis of …
The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …
About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on …
Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ (ADXS) stock rallied today as the …
The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy …
Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis (EXEL) and Daiichi Sankyo (
The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. …
Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed …
A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What …
Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is …
Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi supplemental biological license …
The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles …
Exelixis & Aerie Have Good News Exelixis’ Good News about Cabometyx Takeda Pharmaceuticals applied to the …
About Trovagene Trovagene (TROV) is still a clinical-stage company. The precision cancer medicine approach is practicing what …
Zolgensma Findings The FDA submission of the gene therapy product Zolgensma was based on positive findings …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
